Legal Opinion
Teva Pharmaceuticals, USA, Inc. v. Leavitt
Court of Appeals for the D.C. Circuit
Decided November 7, 2008No. 08-5141PublishedCited by 33 opinions
1Opinion of the Court
Opinion for the Court filed by Circuit Judge BROWN, in which Circuit Judge KAVANAUGH joins.
Opinion concurring in the judgment filed by Senior Circuit Judge WILLIAMS.
BROWN, Circuit Judge:
The Hatch-Waxman Amendments help to expedite the marketing of generic drugs. Drug Price Competition and Patent Term Restoration Act of 1984, Pub.L. No. 98-417, § 101, 98 Stat. 1585, 1585 (1984). Getting a new “branded” drug to market is a time-consuming process. The manufacturer must file a New Drug Application (NDA) with the Food and Drug Administration (FDA), showing the new drug is safe and effective and…
2Cases cited10 opinions
- Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 1984
- Yee v. City of EscondidoSupreme Court of the United States · 1992
- Amer Bioscience Inc v. Thompson, Tommy G.Court of Appeals for the D.C. Circuit · 2001
- Mova Pharmaceutical Corp. v. ShalalaCourt of Appeals for the D.C. Circuit · 1998
- Engine Manufacturers Ass'n v. U.S. Environmental Protection AgencyCourt of Appeals for the D.C. Circuit · 1996
5 more not listed; retrieve them via the Exa API.
3Cited by33 opinions
- In re Niaspan Antitrust LitigationDistrict Court, E.D. Pennsylvania · 2014
- Teva Pharmaceuticals USA, Inc. v. SebeliusCourt of Appeals for the D.C. Circuit · 2010
- Defenders of Wildlife & Center for Biological Diversity v. JewellCourt of Appeals for the D.C. Circuit · 2016
- Arkansas Public Employees Retirement System v. Harman International Industries Inc.Court of Appeals for the D.C. Circuit · 2015
- Actavis Elizabeth LLC v. United States Food & Drug AdministrationCourt of Appeals for the D.C. Circuit · 2010
28 more not listed; retrieve them via the Exa API.